Literature DB >> 9230164

Response of symptomatic myocardial ischemia in ischemic cardiomyopathy to intensive vasodilator therapy.

T B Levine1, A B Levine, A Vincenzi, S J Keteyian, J Billings, M Lesch.   

Abstract

To determine the cardiovascular protective effects of angiotensin-converting enzyme inhibitors, we examined the response to intensive vasodilator therapy in patients with ischemic cardiomyopathy and ongoing angina pectoris. We found that for patients with ischemic cardiomyopathy and ongoing active angina, intensive vasodilator therapy with angiotensin-converting enzyme inhibition and nitrates improved not only heart failure-related symptoms, but also resulted in a significant improvement in symptomatic ischemia and ischemia-related morbid events.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230164     DOI: 10.1016/s0002-9149(97)00322-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  1 in total

1.  Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study.

Authors:  Nicolas W Shammas; Gail A Shammas; Kathleen Keyes; Shawna Duske; Ryan Kelly; Michael Jerin
Journal:  Ther Clin Risk Manag       Date:  2015-03-23       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.